1992;42:452 458. 187. Woo KT, Choong HL, Wong KS, et al. Aliskiren and losartan trial in non- diabetic chronic kidney disease. J Renin Angiotensin Aldosterone Syst. 2014;15:515 522. 188. Mimura T, Takenaka T, Kanno Y, et al. Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases. J Hum Hypertens. 2008;22:38 47. 188a. Ihle BU, Whitworth JA, Shahinfar S, et al. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insuf ciency: a controlled double-blind trial. Am J Kidney Dis. 1996;27:489 495. 189. Cinotti GA, Zucchelli PC, Collaborative Study Group. Effect of Lisinopril on the progression of renal insuf ciency in mild proteinuric non- diabetic nephropathies. Nephrol Dial Transplant. 2001;16:961 966. 190. Shen PC, He LQ, Yang XJ, Cao H X. Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. J Investig Med. 2012;60:1041 1047. 191. Nakamura T, Kanno Y, Takenaka T, Suzuki H. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insuf ciency. Hypertens Res. 2005;28: 415 423. 192. Ando K, Ohtsu H, Uchida S, et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:944 953. 193. Chung EYM, Ruospo M, Natale P, et al. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database of Syst Rev. 2020;10:CD007004. 194. Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol. 2009;54:505 512. 195. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11 21. 196. 